Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4631 | 14402-89-2 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Sodium nitroprusside interacts with oxyhemoglobin to produce methemoglobin, cyanide, and nitric oxide (NO). NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins.
|
| Dose | Unit | Route |
|---|---|---|
| 50 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 25, 2021 | PMDA | MARUISHI PHARMACEUTICAL Co., Ltd | |
| May 10, 1974 | FDA | ROCHE |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 76.15 | 64.40 | 36 | 508 | 287810 | 90340093 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Fear | 52.32 | 37.46 | 16 | 874 | 10949 | 42609496 |
| Injury | 44.77 | 37.46 | 17 | 873 | 22299 | 42598146 |
| Anhedonia | 40.08 | 37.46 | 12 | 878 | 7628 | 42612817 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Fear | 80.71 | 40.56 | 24 | 1465 | 23169 | 110564641 |
| Renal failure | 77.05 | 40.56 | 44 | 1445 | 226530 | 110361280 |
| Toxicity to various agents | 69.98 | 40.56 | 55 | 1434 | 480500 | 110107310 |
| Anhedonia | 62.63 | 40.56 | 18 | 1471 | 15410 | 110572400 |
| Renal injury | 59.20 | 40.56 | 18 | 1471 | 18695 | 110569115 |
| Unevaluable event | 58.69 | 40.56 | 24 | 1465 | 59203 | 110528607 |
| Multiple organ dysfunction syndrome | 50.23 | 40.56 | 29 | 1460 | 151681 | 110436129 |
| Hypotension | 49.74 | 40.56 | 47 | 1442 | 523802 | 110064008 |
| Emotional distress | 47.25 | 40.56 | 19 | 1470 | 44828 | 110542982 |
None
| Source | Code | Description |
|---|---|---|
| ATC | C02DD01 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON Nitroferricyanide derivatives |
| FDA PE | N0000009909 | Vasodilation |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D007202 | Indicators and Reagents |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D020030 | Nitric Oxide Donors |
| FDA EPC | N0000175940 | Vasodilator |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:50566 | nitric oxide donor |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:176497 | geroprotector |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Acute heart failure | indication | 56675007 | |
| Malignant essential hypertension | indication | 78975002 | DOID:10823 |
| Decompensated cardiac failure | indication | 195111005 | |
| Hypertensive urgency | indication | 443482000 | |
| Acute exacerbation of chronic congestive heart failure | indication | 698296002 | |
| Controlled Hypotension | indication | ||
| Coarctation of aorta | contraindication | 7305005 | |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Hypovolemia | contraindication | 28560003 | |
| Acute cerebrovascular insufficiency | contraindication | 29322000 | |
| Tobacco amblyopia | contraindication | 30483005 | |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Acute nephropathy | contraindication | 58574008 | |
| Leber's optic atrophy | contraindication | 58610003 | DOID:705 |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Disorder of brain | contraindication | 81308009 | DOID:936 |
| Hyponatremia | contraindication | 89627008 | |
| Cobalamin deficiency | contraindication | 190634004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Soluble guanylate cyclase | Enzyme | ACTIVATOR | CHEMBL | CHEMBL | |||||
| Atrial natriuretic peptide receptor 1 | Enzyme | WOMBAT-PK |
| ID | Source |
|---|---|
| D00614 | KEGG_DRUG |
| 4017812 | VUID |
| N0000178982 | NUI |
| 15078-28-1 | SECONDARY_CAS_RN |
| 13755-38-9 | SECONDARY_CAS_RN |
| 4017812 | VANDF |
| CHEBI:7596 | CHEBI |
| CHEMBL2097081 | ChEMBL_ID |
| CHEMBL136478 | ChEMBL_ID |
| DB00325 | DRUGBANK_ID |
| 169D1260KM | UNII |
| 7476 | RXNORM |
| 1098 | MMSL |
| 5489 | MMSL |
| NOCODE | MMSL |
| d00136 | MMSL |
| 000664 | NDDF |
| 372860000 | SNOMEDCT_US |
| 387139005 | SNOMEDCT_US |
| 8163008 | SNOMEDCT_US |
| C0028193 | UMLSCUI |
| D009599 | MESH_DESCRIPTOR_UI |
| 73415791 | PUBCHEM_CID |
| 169D1260KM | INXIGHT DRUGS |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| sodium nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-131 | INJECTION, SOLUTION, CONCENTRATE | 50 mg | INTRAVENOUS | ANDA | 19 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-132 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 17 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-133 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 17 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-134 | INJECTION, SOLUTION | 0.50 mg | INTRAVENOUS | ANDA | 17 sections |
| SODIUM NITROPRUSSIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-265 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 12 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-587 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | ANDA | 20 sections |
| NIPRIDE RTU | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1006 | INJECTION, SOLUTION | 0.50 mg | INTRAVENOUS | NDA | 17 sections |
| NIPRIDE RTU | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1018 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | NDA | 17 sections |
| NIPRIDE RTU | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1029 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | NDA | 17 sections |
| SODIUM NITROPRUSSIDE | Human Prescription Drug Label | 1 | 55150-320 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 12 sections |
| Sodium Nitroprusside | Human Prescription Drug Label | 1 | 65145-101 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 19 sections |
| Sodium Nitroprusside | Human Prescription Drug Label | 1 | 65145-101 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 19 sections |
| Sodium nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-839 | INJECTION, SOLUTION, CONCENTRATE | 25 mg | INTRAVENOUS | ANDA | 19 sections |
| Sodium nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-999 | INJECTION, SOLUTION, CONCENTRATE | 25 mg | INTRAVENOUS | ANDA | 19 sections |
| Sodium nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-999 | INJECTION, SOLUTION, CONCENTRATE | 25 mg | INTRAVENOUS | ANDA | 19 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-261 | INJECTION, SOLUTION, CONCENTRATE | 25 mg | INTRAVENOUS | ANDA | 17 sections |
| Sodium nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1189 | INJECTION | 25 mg | INTRAVENOUS | ANDA | 18 sections |
| sodium nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-028 | INJECTION, SOLUTION, CONCENTRATE | 50 mg | INTRAVENOUS | ANDA | 19 sections |
| sodium nitroprusside in 0.9% sodium chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-205 | INJECTION | 0.20 mg | INTRAVENOUS | ANDA | 25 sections |
| sodium nitroprusside in 0.9% sodium chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-206 | INJECTION | 0.20 mg | INTRAVENOUS | ANDA | 25 sections |
| sodium nitroprusside in 0.9% sodium chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-207 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 25 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-126 | INJECTION, SOLUTION, CONCENTRATE | 50 mg | INTRAVENOUS | ANDA | 13 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-202 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | ANDA | 22 sections |
| Sodium Nitroprusside | Human Prescription Drug Label | 1 | 71839-120 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 19 sections |
| SODIUM NITROPRUSSIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-105 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 12 sections |
| SODIUM NITROPRUSSIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-305 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 13 sections |
| Sodium Nitroprusside | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75907-290 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | ANDA | 20 sections |